NCT00102492

Study Of GW679769 In Major Depressive Disorder

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 356 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

This is a placebo-controlled, fixed dose study that will evaluate the efficacy and safety of GW679769 in subjects with major depressive disorder.

Conditions

• Depressive Disorder, Major
• Major Depressive Disorder (MDD)

Interventions

Type	Name	Description
DRUG	GW679769

Timeline

• Start date: 2004-10-01
• Primary completion: 2006-09-01
• Completion: 2006-09-01
• First posted: 2005-01-31
• Last updated: 2015-04-16

Locations

31 sites across 2 countries: United States, Canada